Actuate Therapeutics Inc (ACTU) Stock

Actuate Therapeutics Inc (ACTU) is a Healthcare stock trading at $1.36 (as of 2026-07-21), with a market capitalization of $32.54M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies, including Elraglusib Injection, a glycogen synthase kinase-3 inhibitor being studied for metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for Ewing sarcoma, metastatic melanoma, and colorectal cancer.

Understand Actuate Therapeutics Inc: how it makes money

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies, led by Elraglusib Injection, and it has not shown meaningful commercial revenue in the provided latest quarter.

Because Actuate is clinical-stage with no reportable product segments, its ability to generate future profits depends primarily on Elraglusib trial results (survival, response, and comparative risk reductions) supporting regulatory approval and eventual commercialization.

Business quality (Weak): Clinical data for Elraglusib in metastatic pancreatic cancer show improvements on several endpoints versus control, but the business still lacks demonstrated commercial revenue and operates at a very large loss in the latest provided quarter.

Bull case

  • Overall survival improvement signals: Elraglusib plus Gemcitabine and Nab-Paclitaxel shows a hazard ratio for overall survival of 0.63 versus control.
  • Higher longer-term survival on a one-year basis: One-year survival rate is 43.6 percent for Elraglusib plus Gemcitabine and Nab-Paclitaxel versus 22.5 percent for the Gemcitabine and Nab-Paclitaxel control.
  • Improved median overall survival: Median overall survival is 9.3 months with Elraglusib plus Gemcitabine and Nab-Paclitaxel versus 7.2 months with the control.

Bear case

  • No commercial revenue in the latest provided quarter: For the period 2026-03-31, revenue is shown as 0.0B in the provided data, consistent with an early-stage development profile.
  • Material ongoing operating losses: The provided operating margin is extremely negative at -6691.7 percent for 2026-03-31, reflecting heavy losses while therapies are still in development.
  • Clinical success risk remains: Even with positive comparative results on some endpoints, future development, regulatory decisions, and outcomes in additional studies are not guaranteed.
Valuation — source: SEC EDGAR (first-party)
Price$1.36
Market Cap$32.54M
Price / Book32.90
Price / Sales113.96
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$287710.00
Net Margin-7725.8%
Revenue Growth (YoY)29.4%
EPS Growth (YoY)-67.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-16.85 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBIOS Capital Management, LP ($27.54M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODaniel Schmitt
Employees10
CountryUS
IPO Date2024-08-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Actinium Pharmaceuticals, Inc. (ATNM)
  • Lite Strategy, Inc. (LITS)
  • MIRA Pharmaceuticals, Inc. (MIRA)
  • IGC Pharma, Inc. (IGC)
  • Lantern Pharma Inc. (LTRN)
  • Daré Bioscience, Inc. (DARE)
  • BeyondSpring Inc. (BYSI)
  • NextCure, Inc. (NXTC)
ACTU earnings history · ACTU institutional & insider holders · ACTU KPIs & operating metrics · ACTU financials · ACTU investor presentations & press releases · ACTU SEC filings · ACTU peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.